Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ranson

Showing results (91-100 of 158) with videos related to

Pageof 16
Sort By:
The Journal of Biological Chemistry|September 14, 2001
Interaction between the P14 residue and strand 2 of beta-sheet B is critical for reactive center loop insertion in plasminogen activator inhibitor-2D N Saunders, L Jankova, S J Harrop, et al.
British Journal of Cancer|February 1, 1995
VAD chemotherapy as remission induction for multiple myelomaH Anderson, J H Scarffe, M Ranson, et al.
British Journal of Cancer|September 14, 2006
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancerS C White, P Lorigan, G P Margison, et al.
Thrombosis and Haemostasis|November 5, 2024
Brisk Walking Pace Offsets Venous Thromboembolism Risk Equivalent to Established Monogenic MutationsWenyan Xian, Yifan Tao, Chong You, et al.
Current Cancer Drug Targets|November 25, 2011
Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growthK L Vine, V Indira Chandran, J M Locke, et al.
British Journal of Cancer|February 9, 2005
Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II studyJ W Valle, A Dangoor, J Beech, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 11, 2013
Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: a short communicationA Greystoke, G Harris, M Jenkins, et al.
Brain Communications|August 17, 2022
Development of prognostic models for survival and care status in sporadic Creutzfeldt-Jakob diseaseAkın Nihat, Janice M Ranson, Dominique Harris, et al.
JAMA Neurology|December 26, 2023
Risk Factors for Young-Onset Dementia in the UK BiobankStevie Hendriks, Janice M Ranson, Kirsten Peetoom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanomaS Danson, P Lorigan, A Arance, et al.
Pageof 16

Showing results (91-100 of 158) with videos related to

Sort By:
Pageof 16
The Journal of Biological Chemistry|September 14, 2001
Interaction between the P14 residue and strand 2 of beta-sheet B is critical for reactive center loop insertion in plasminogen activator inhibitor-2D N Saunders, L Jankova, S J Harrop, et al.
British Journal of Cancer|February 1, 1995
VAD chemotherapy as remission induction for multiple myelomaH Anderson, J H Scarffe, M Ranson, et al.
British Journal of Cancer|September 14, 2006
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancerS C White, P Lorigan, G P Margison, et al.
Thrombosis and Haemostasis|November 5, 2024
Brisk Walking Pace Offsets Venous Thromboembolism Risk Equivalent to Established Monogenic MutationsWenyan Xian, Yifan Tao, Chong You, et al.
Current Cancer Drug Targets|November 25, 2011
Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growthK L Vine, V Indira Chandran, J M Locke, et al.
British Journal of Cancer|February 9, 2005
Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II studyJ W Valle, A Dangoor, J Beech, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 11, 2013
Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: a short communicationA Greystoke, G Harris, M Jenkins, et al.
Brain Communications|August 17, 2022
Development of prognostic models for survival and care status in sporadic Creutzfeldt-Jakob diseaseAkın Nihat, Janice M Ranson, Dominique Harris, et al.
JAMA Neurology|December 26, 2023
Risk Factors for Young-Onset Dementia in the UK BiobankStevie Hendriks, Janice M Ranson, Kirsten Peetoom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanomaS Danson, P Lorigan, A Arance, et al.
Pageof 16